Stellungnahme des Berufsverbandes der Augenärzte Deutschlands, der Deutschen Ophthalmologischen Gesellschaft und der Retinologischen Gesellschaft zur Chorioretinopathia centralis serosa (CCS)

Stand Januar 2018
  • Berufsverband der Augenärzte Deutschlands e. V. (BAV)
  • Deutsche Ophthalmologische Gesellschaft (DOG)
  • Retinologische Gesellschaft e. V. (RG)
Leitlinien, Stellungnahmen und Empfehlungen
  • 54 Downloads

Statement and recommendation of the Professional Association of German Ophthalmologists (BVA), the German Ophthalmological Society (DOG) and the German Retina Society (RG) on central serous chorioretinopathy

Situation January 2018

Notes

Redaktionskomitee

PD Dr. Dr. Clemens Lange, Freiburg (federführend)

PD Dr. Felix Treumer, Kiel

Prof. Dr. Bernd Bertram, Aachen

Prof. Dr. Nicolas Feltgen, Göttingen

Prof. Dr. Hans Hoerauf, Göttingen

Prof. Dr. Daniel Pauleikhoff, Münster

Prof. Dr. Johann Roider, Kiel

Einhaltung ethischer Richtlinien

Interessenkonflikt

Siehe (Tab. 1) im Anhang.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Alkin Z, Osmanbasoglu OA, Ozkaya A, Karatas G, Yazici AT (2013) Topical nepafenac in treatment of acute central serous chorioretinopathy. Med Hypothesis Discov Innov Ophthalmol 2:96–101PubMedPubMedCentralGoogle Scholar
  2. 2.
    Ayata A, Tatlipinar S, Kar T, Unal M, Ersanli D, Bilge AH (2009) Near-infrared and short-wavelength autofluorescence imaging in central serous chorioretinopathy. Br J Ophthalmol 93:79–82CrossRefPubMedGoogle Scholar
  3. 3.
    Bae SH, Heo JW, Kim C, Kim TW, Lee JY, Song SJ, Park TK, Moon SW, Chung H (2011) A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy. Am J Ophthalmol 152:784–792.e2CrossRefPubMedGoogle Scholar
  4. 4.
    Battaglia Parodi M, Da Pozzo S, Ravalico G (2003) Photodynamic therapy in chronic central serous chorioretinopathy. Retina 23:235–237CrossRefPubMedGoogle Scholar
  5. 5.
    Bonini Filho MA, de Carlo TE, Ferrara D, Adhi M, Baumal CR, Witkin AJ, Reichel E, Duker JS, Waheed NK (2015) Association of choroidal neovascularization and central serous chorioretinopathy with optical coherence tomography angiography. JAMA Ophthalmol 133:899–906CrossRefPubMedGoogle Scholar
  6. 6.
    Bousquet E, Beydoun T, Rothschild P‑R, Bergin C, Zhao M, Batista R, Brandely M‑L, Couraud B, Farman N, Gaudric A et al (2015) Spironolactone for nonresolving central serous chorioretinopathy. Retina 35:2505–2515CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Bousquet E, Bonnin S, Mrejen S, Krivosic V, Tadayoni R, Gaudric A (2017) Optical coherence tomography of flat irregular pigment epithelium detachment in chronic central serous chorioretinopathy. Retina.  https://doi.org/10.1097/IAE.0000000000001580 Google Scholar
  8. 8.
    Bujarborua D (2001) Long-term follow-up of idiopathic central serous chorioretinopathy without laser. Acta Ophthalmol Scand 79:417–421CrossRefPubMedGoogle Scholar
  9. 9.
    Bujarborua D, Chatterjee S, Choudhury A, Bori G, Sarma AK (2005) Fluorescein angiographic features of asymptomatic eyes in central serous chorioretinopathy. Retina 25:422–429CrossRefPubMedGoogle Scholar
  10. 10.
    Bujarborua D, Nagpal PN, Deka M (2010) Smokestack leak in central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 248:339–351CrossRefPubMedGoogle Scholar
  11. 11.
    Caccavale A, Romanazzi F, Imparato M, Negri A, Morano A, Ferentini F (2010) Low-dose aspirin as treatment for central serous chorioretinopathy. Clin Ophthalmol 4:899–903CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Chan W‑M, Lam DSC, Lai TYY, Tam BSM, Liu DTL, Chan CKM (2003) Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol 87:1453–1458CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Chan W‑M, Lai TYY, Lai RYK, Liu DTL, Lam DSC (2008) Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology 115:1756–1765CrossRefPubMedGoogle Scholar
  14. 14.
    Cheng C‑K, Chang C‑K, Peng C‑H (2017) Comparison of photodynamic therapy using half-dose of verteporfin or half-fluence of laser light for the treatment of chronic central serous chorioretinopathy. Retina 37:325–333CrossRefPubMedGoogle Scholar
  15. 15.
    Chong C‑F, Yang D, Pham TQ, Liu H (2012) A novel treatment of central serous chorioretinopathy with topical anti-inflammatory therapy. BMJ Case Rep.  https://doi.org/10.1136/bcr-2012-006970 PubMedPubMedCentralGoogle Scholar
  16. 16.
    Chuang EL, Sharp DM, Fitzke FW, Kemp CM, Holden AL, Bird AC (1987) Retinal dysfunction in central serous retinopathy. Eye (Lond) 1(Pt 1):120–125CrossRefGoogle Scholar
  17. 17.
    Chung Y‑R, Seo EJ, Lew HM, Lee KH (2013) Lack of positive effect of intravitreal bevacizumab in central serous chorioretinopathy: meta-analysis and review. Eye 27:1339–1346CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Daruich A, Matet A, Dirani A, Bousquet E, Zhao M, Farman N, Jaisser F, Behar-Cohen F (2015) Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res 48:82.  https://doi.org/10.1016/j.preteyeres.2015.05.003 CrossRefPubMedGoogle Scholar
  19. 19.
    Daruich A, Matet A, Marchionno L, De Azevedo J‑D, Ambresin A, Mantel I, Behar-Cohen F (2017) Acute central serous chorioretinopathy: factors influencing episode duration. Retina 37(10):1905.  https://doi.org/10.1097/IAE.0000000000001443 CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Delori FC, Dorey CK, Staurenghi G, Arend O, Goger DG, Weiter JJ (1995) In vivo fluorescence of the ocular fundus exhibits retinal pigment epithelium lipofuscin characteristics. Invest Ophthalmol Vis Sci 36:718–729PubMedGoogle Scholar
  21. 21.
    Desai UR, Alhalel AA, Campen TJ, Schiffman RM, Edwards PA, Jacobsen GR (2003) Central serous chorioretinopathy in African Americans. J Natl Med Assoc 95:553–559PubMedPubMedCentralGoogle Scholar
  22. 22.
    Elsner H, Pörksen E, Klatt C, Bunse A, Theisen-Kunde D, Brinkmann R, Birngruber R, Laqua H, Roider J (2006) Selective retina therapy in patients with central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 244(12):1638–1645CrossRefPubMedGoogle Scholar
  23. 23.
    Ficker L, Vafidis G, While A, Leaver P (1988) Long-term follow-up of a prospective trial of argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol 72:829–834CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Forooghian F, Meleth AD, Cukras C, Chew EY, Wong WT, Meyerle CB (2011) Finasteride for chronic central serous chorioretinopathy. Retina 31:766–771CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    French DD, Margo CE (2010) Central serous chorioretinopathy and phosphodiesterase-5 inhibitors: a case-control postmarketing surveillance study. Retina 30:271–274CrossRefPubMedGoogle Scholar
  26. 26.
    Gäckle HC, Lang GE, Freissler KA, Lang GK (1998) Central serous chorioretinopathy. Clinical, fluorescein angiography and demographic aspects. Ophthalmologe 95(8):529–533CrossRefPubMedGoogle Scholar
  27. 27.
    de Gasparo M, Joss U, Ramjoué HP, Whitebread SE, Haenni H, Schenkel L, Kraehenbuehl C, Biollaz M, Grob J, Schmidlin J (1987) Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther 240:650–656PubMedGoogle Scholar
  28. 28.
    Gass JD, Little H (1995) Bilateral bullous exudative retinal detachment complicating idiopathic central serous chorioretinopathy during systemic corticosteroid therapy. Ophthalmology 102:737–747CrossRefPubMedGoogle Scholar
  29. 29.
    Gilbert CM, Owens SL, Smith PD, Fine SL (1984) Long-term follow-up of central serous chorioretinopathy. Br J Ophthalmol 68:815–820CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Haimovici R, Rumelt S, Melby J (2003) Endocrine abnormalities in patients with central serous chorioretinopathy. Ophthalmology 110:698–703CrossRefPubMedGoogle Scholar
  31. 31.
    Heinrich MR (1974) Central serous retinopathy and alpha-blockaders. Bull Soc Ophtalmol Fr 74:681–683PubMedGoogle Scholar
  32. 32.
    Iacono P, Battaglia PM, Papayannis A, La Spina C, Varano M, Bandello F (2015) Acute central serous chorioretinopathy: a correlation study between fundus autofluorescence and spectral-domain OCT. Graefes Arch Clin Exp Ophthalmol 253:1889–1897CrossRefPubMedGoogle Scholar
  33. 33.
    Iida T, Yannuzzi LA, Spaide RF, Borodoker N, Carvalho CA, Negrao S (2003) Cystoid macular degeneration in chronic central serous chorioretinopathy. Retina 23:1–7 (quiz 137-8)CrossRefPubMedGoogle Scholar
  34. 34.
    Jain AK, Kaines A, Schwartz S (2010) Bilateral central serous chorioretinopathy resolving rapidly with treatment for obstructive sleep apnea. Graefes Arch Clin Exp Ophthalmol 248:1037–1039CrossRefPubMedGoogle Scholar
  35. 35.
    de Jong EK, Breukink MB, Schellevis RL, Bakker B, Mohr JK, Fauser S, Keunen JEE, Hoyng CB, den Hollander AI, Boon CJF (2015) Chronic central serous chorioretinopathy is associated with genetic variants implicated in age-related macular degeneration. Ophthalmology 122:562–570CrossRefPubMedGoogle Scholar
  36. 36.
    Katsimpris JM, Pournaras CJ, Sehgelmeble CW, Petropoulos IK (2007) Severe bilateral central serous chorioretinopathy in a black patient: 16 years follow-up. Graefes Arch Clin Exp Ophthalmol 245:460–463CrossRefPubMedGoogle Scholar
  37. 37.
    Kitaya N, Nagaoka T, Hikichi T, Sugawara R, Fukui K, Ishiko S, Yoshida A (2003) Features of abnormal choroidal circulation in central serous chorioretinopathy. Br J Ophthalmol 87:709–712CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Kitzmann AS, Pulido JS, Diehl NN, Hodge DO, Burke JP (2008) The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980–2002. Ophthalmology 115:169–173CrossRefPubMedGoogle Scholar
  39. 39.
    Klatt C, Saeger M, Oppermann T, Pörksen E, Treumer F, Hillenkamp J, Fritzer E, Brinkmann R, Birngruber R, Roider J (2011) Selective retina therapy for acute central serous chorioretinopathy. Br J Ophthalmol 95:83–88CrossRefPubMedGoogle Scholar
  40. 40.
    Lai TYY, Staurenghi G, Lanzetta P, Holz FG, Melissa Liew SH, Desset-Brethes S, Staines H, Hykin PG, MINERVA study group (2017) Efficacy and safety of ranibizumab for the treatment of choroidal neovascularization due to uncommon cause: twelve-month results of the MINERVA study. Retina.  https://doi.org/10.1097/IAE.0000000000001744 Google Scholar
  41. 41.
    Lainscak M, Pelliccia F, Rosano G, Vitale C, Schiariti M, Greco C, Speziale G, Gaudio C (2015) Safety profile of mineralocorticoid receptor antagonists: spironolactone and eplerenone. Int J Cardiol 200:25–29CrossRefPubMedGoogle Scholar
  42. 42.
    Lavinsky D, Sramek C, Wang J, Huie P, Dalal R, Mandel Y, Palanker D (2014) Subvisible retinal laser therapy: titration algorithm and tissue response. Retina 34:87–97CrossRefPubMedGoogle Scholar
  43. 43.
    Leaver P, Williams C (1979) Argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol 63:674–677CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Lee H, Lee J, Chung H, Kim HC (2016) Baseline spectral domain optical coherence tomographic hyperreflective foci as a predictor of visual outcome and recurrence for central serous chorioretinopathy. Retina 36:1372–1380CrossRefPubMedGoogle Scholar
  45. 45.
    Lim JI, Spee C, Hinton DR (2010) A comparison of hypoxia-inducible factor-alpha in surgically excised neovascular membranes of patients with diabetes compared with idiopathic epiretinal membranes in nondiabetic patients. Retina 30:1472–1478CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Lipowski ZJ, Kiriakos RZ (1971) Psychosomatic aspects of central serous retinopathy. A review and case report. Psychosomatics 12:398–401CrossRefPubMedGoogle Scholar
  47. 47.
    Liu B, Deng T, Zhang J (2016) Risk factors for central serous chorioretinopathy: a systematic review and meta-analysis. Retina 36:9–19CrossRefPubMedGoogle Scholar
  48. 48.
    Ma J, Meng N, Xu X, Zhou F, Qu Y (2014) System review and meta-analysis on photodynamic therapy in central serous chorioretinopathy. Acta Ophthalmol 92:e594–e601CrossRefPubMedGoogle Scholar
  49. 49.
    Maruko I, Iida T, Sugano Y, Ojima A, Ogasawara M, Spaide RF (2010) Subfoveal choroidal thickness after treatment of central serous chorioretinopathy. Ophthalmology 117:1792–1799CrossRefPubMedGoogle Scholar
  50. 50.
    Matet A, Daruich A, Zola M, Behar-Cohen F (2017) Risk factors for recurrences of central serous chorioretinopathy. Retina.  https://doi.org/10.1097/IAE.0000000000001729 Google Scholar
  51. 51.
    Matsumoto H, Kishi S, Otani T, Sato T (2008) Elongation of photoreceptor outer segment in central serous chorioretinopathy. Am J Ophthalmol 145:162–168CrossRefPubMedGoogle Scholar
  52. 52.
    Meyerle CB, Freund KB, Bhatnagar P, Shah V, Yannuzzi LA (2007) Ketoconazole in the treatment of chronic idiopathic central serous chorioretinopathy. Retina 27:943–946CrossRefPubMedGoogle Scholar
  53. 53.
    Nicholson B, Noble J, Forooghian F, Meyerle C (2013) Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol 58:103–126CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Nicholson BP, Atchison E, Idris AA, Bakri SJ (2017) Central serous chorioretinopathy and glucocorticoids: an update on evidence for association. Surv Ophthalmol 63(1):1–8.  https://doi.org/10.1016/j.survophthal.2017.06.008 CrossRefPubMedGoogle Scholar
  55. 55.
    Nicolò M, Zoli D, Musolino M, Traverso CE (2012) Association between the efficacy of half-dose photodynamic therapy with indocyanine green angiography and optical coherence tomography findings in the treatment of central serous chorioretinopathy. Am J Ophthalmol 153:474–480.e1CrossRefPubMedGoogle Scholar
  56. 56.
    Nielsen JS, Jampol LM (2011) Oral mifepristone for chronic central serous chorioretinopathy. Retina 31:1928–1936CrossRefPubMedGoogle Scholar
  57. 57.
    O’Keefe JH, Abuissa H, Pitt B (2008) Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS. Diabetes Obes Metab 10:492–497CrossRefPubMedGoogle Scholar
  58. 58.
    Peiretti E, Ferrara DC, Caminiti G, Mura M, Hughes J (2015) Choroidal neovascularization in caucasian patients with longstanding central serous chorioretinopathy. Retina 35:1360–1367CrossRefPubMedGoogle Scholar
  59. 59.
    Piccolino FC, De La Longrais RR, Manea M, Cicinelli S (2008) Posterior cystoid retinal degeneration in central serous chorioretinopathy. Retina 28:1008–1012CrossRefPubMedGoogle Scholar
  60. 60.
    Pichi F, Carrai P, Ciardella A, Behar-Cohen F, Nucci P, Central Serous Chorioretinopathy Study Group (2016) Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy. Int Ophthalmol 37(5):1115.  https://doi.org/10.1007/s10792-016-0377-2 CrossRefGoogle Scholar
  61. 61.
    Pikkel J, Beiran I, Ophir A, Miller B (2002) Acetazolamide for central serous retinopathy. Ophthalmology 109:1723–1725CrossRefPubMedGoogle Scholar
  62. 62.
    Pitt B, Bakris G, Ruilope LM, DiCarlo L, Mukherjee R, Investigators EPHESUS (2008) Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation 118:1643–1650CrossRefPubMedGoogle Scholar
  63. 63.
    Quaranta-El Maftouhi M, El Maftouhi A, Eandi CM (2015) Chronic central serous chorioretinopathy imaged by optical coherence tomographic angiography. Am J Ophthalmol 160:581–587.e1CrossRefPubMedGoogle Scholar
  64. 64.
    Rahbani-Nobar MB, Javadzadeh A, Ghojazadeh L, Rafeey M, Ghorbanihaghjo A (2011) The effect of helicobacter pylori treatment on remission of idiopathic central serous chorioretinopathy. Mol Vis 17:99–103PubMedPubMedCentralGoogle Scholar
  65. 65.
    Rahimy E, Pitcher JD, Hsu J, Adam MK, Shahlaee A, Samara WA, Vander JF, Kaiser RS, Chiang A, Spirn MJ et al (2017) A randomized double-blind placebo-control pilot study of eplerenone for the treatment of central serous chorioretinopathy (ecselsior). Retina.  https://doi.org/10.1097/IAE.0000000000001649 Google Scholar
  66. 66.
    Reibaldi M, Cardascia N, Longo A, Furino C, Avitabile T, Faro S, Sanfilippo M, Russo A, Uva MG, Munno F et al (2010) Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial. Am J Ophthalmol 149:307–315.e2CrossRefPubMedGoogle Scholar
  67. 67.
    Robertson DM, Ilstrup D (1983) Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy. Am J Ophthalmol 95:457–466CrossRefPubMedGoogle Scholar
  68. 68.
    Roider J, Brinkmann R, Wirbelauer C, Laqua H, Birngruber R (2000) Subthreshold (RPE) photocoagulation in macular diseases – a pilot study. Br J Ophthalmol 84:40–47CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Salehi M, Wenick AS, Law HA, Evans JR, Gehlbach P (2015) Interventions for central serous chorioretinopathy: a network meta-analysis. Cochrane Database Syst Rev.  https://doi.org/10.1002/14651858.CD011841.pub2 PubMedPubMedCentralGoogle Scholar
  70. 70.
    Scholz P, Altay L, Fauser S (2017) A review of subthreshold micropulse laser for treatment of macular disorders. Adv Ther 34:1528–1555CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Schubert C, Pryds A, Zeng S, Xie Y, Freund KB, Spaide RF, Merriam JC, Barbazetto I, Slakter JS, Chang S et al (2014) Cadherin 5 is regulated by corticosteroids and associated with central serous chorioretinopathy. Hum Mutat 35:859–867CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Schwartz R, Habot-Wilner Z, Martinez MR, Nutman A, Goldenberg D, Cohen S, Shulman S, Guzner-Gur H, Loewenstein A, Goldstein M (2017) Eplerenone for chronic central serous chorioretinopathy-a randomized controlled prospective study. Acta Ophthalmol 95(7):e610.  https://doi.org/10.1111/aos.13491 CrossRefPubMedGoogle Scholar
  73. 73.
    Senturk F, Karacorlu M, Ozdemir H, Karacorlu SA, Uysal O (2011) Microperimetric changes after photodynamic therapy for central serous chorioretinopathy. Am J Ophthalmol 151:303–309.e1CrossRefPubMedGoogle Scholar
  74. 74.
    Sharma T, Shah N, Rao M, Gopal L, Shanmugam MP, Gopalakrishnan M, Bhende P, Bhende M, Shetty NS, Baluswamy S (2004) Visual outcome after discontinuation of corticosteroids in atypical severe central serous chorioretinopathy. Ophthalmology 111:1708–1714CrossRefPubMedGoogle Scholar
  75. 75.
    Shin MC, Lim JW (2011) Concentration of cytokines in the aqueous humor of patients with central serous chorioretinopathy. Retina 31:1937–1943CrossRefPubMedGoogle Scholar
  76. 76.
    Shinojima A, Hirose T, Mori R, Kawamura A, Yuzawa M (2010) Morphologic findings in acute central serous chorioretinopathy using spectral domain-optical coherence tomography with simultaneous angiography. Retina 30:193–202CrossRefPubMedGoogle Scholar
  77. 77.
    Shinojima A, Sawa M, Sekiryu T, Oshima Y, Mori R, Hara C, Sugano Y, Kato A, Asato H, Yuzawa M et al (2017) A Multicenter randomized controlled study of antioxidant supplementation with lutein for chronic central serous chorioretinopathy. Ophthalmologica 237:159–166.  https://doi.org/10.1159/000455807 CrossRefPubMedGoogle Scholar
  78. 78.
    Shulman S, Goldenberg D, Schwartz R, Habot-Wilner Z, Barak A, Ehrlich N, Loewenstein A, Goldstein M (2016) Oral Rifampin treatment for longstanding chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 254:15–22CrossRefPubMedGoogle Scholar
  79. 79.
    Spaide RF, Klancnik JM (2005) Fundus autofluorescence and central serous chorioretinopathy. Ophthalmology 112:825–833CrossRefPubMedGoogle Scholar
  80. 80.
    Spaide RF, Campeas L, Haas A, Yannuzzi LA, Fisher YL, Guyer DR, Slakter JS, Sorenson JA, Orlock DA (1996a) Central serous chorioretinopathy in younger and older adults. Ophthalmology 103(2080):2070–2079CrossRefPubMedGoogle Scholar
  81. 81.
    Spaide RF, Hall L, Haas A, Campeas L, Yannuzzi LA, Fisher YL, Guyer DR, Slakter JS, Sorenson JA, Orlock DA (1996b) Indocyanine green videoangiography of older patients with central serous chorioretinopathy. Retina 16:203–213CrossRefPubMedGoogle Scholar
  82. 82.
    Spitznas M (1986) Pathogenesis of central serous retinopathy: a new working hypothesis. Graefes Arch Clin Exp Ophthalmol 224:321–324CrossRefPubMedGoogle Scholar
  83. 83.
    Teke MY, Elgin U, Nalcacioglu-Yuksekkaya P, Sen E, Ozdal P, Ozturk F (2014) Comparison of autofluorescence and optical coherence tomography findings in acute and chronic central serous chorioretinopathy. Int J Ophthalmol 7:350–354PubMedPubMedCentralGoogle Scholar
  84. 84.
    Tseng CC, Chen SN. (2015) Long-term efficacy of half-dose photodynamic therapy on chronic central serous chorioretinopathy. Br J Ophthalmol 99(8):1070–1077.  https://doi.org/10.1136/bjophthalmol-2014-305353 Google Scholar
  85. 85.
    Vasconcelos H, Marques I, Santos AR, Melo P, Pires I, Figueira J, de Abreu JF, Cachulo ML, Silva R (2013) Long-term chorioretinal changes after photodynamic therapy for chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 251(7):1697–1705.  https://doi.org/10.1007/s00417-013-2270-2 Google Scholar
  86. 86.
    Verma L, Sinha R, Venkatesh P, Tewari H (2004) Comparative evaluation of diode laser versus argon laser photocoagulation in patients with central serous retinopathy: A pilot, randomized controlled trial [ISRCTN84128484. BMC Ophthalmol 4:15CrossRefPubMedPubMedCentralGoogle Scholar
  87. 87.
    Wolfensberger TJ, Chiang RK, Takeuchi A, Marmor MF (2000) Inhibition of membrane-bound carbonic anhydrase enhances subretinal fluid absorption and retinal adhesiveness. Graefes Arch Clin Exp Ophthalmol 238:76–80CrossRefPubMedGoogle Scholar
  88. 88.
    Wong R, Chopdar A, Brown M (2004) Five to 15 year follow-up of resolved idiopathic central serous chorioretinopathy. Eye 18:262–268CrossRefPubMedGoogle Scholar
  89. 89.
    Wood EH, Karth PA, Sanislo SR, Moshfeghi DM, Palanker DV (2017) Nondamaging retinal laser theray for treatment of central serous chorioretinopathy: what is the evidence? Retina 37:1021–1033CrossRefPubMedGoogle Scholar
  90. 90.
    Wu ZHY, Lai RYK, Yip YWY, Chan WM, Lam DSC, Lai TYY (2011) Improvement in multifocal electroretinography after half-dose verteporfin photodynamic therapy for central serous chorioretinopathy: a randomized placebo-controlled trial. Retina 31:1378–1386CrossRefPubMedGoogle Scholar
  91. 91.
    Yalcinbayir O, Gelisken O, Akova-Budak B, Ozkaya G, Gorkem Cevik S, Yucel AA (2014) Correlation of spectral domain optical coherence tomography findings and visual acuity in central serous chorioretinopathy. Retina 34:705–712CrossRefPubMedGoogle Scholar
  92. 92.
    Yannuzzi LA (1986) Type A behavior and central serous chorioretinopathy. Trans Am Ophthalmol Soc 84:799–845PubMedPubMedCentralGoogle Scholar
  93. 93.
    Yannuzzi LA, Shakin JL, Fisher YL, Altomonte MA (1984) Peripheral retinal detachments and retinal pigment epithelial atrophic tracts secondary to central serous pigment epitheliopathy. Ophthalmology 91:1554–1572CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  • Berufsverband der Augenärzte Deutschlands e. V. (BAV)
    • 1
  • Deutsche Ophthalmologische Gesellschaft (DOG)
    • 2
  • Retinologische Gesellschaft e. V. (RG)
    • 3
  1. 1.Berufsverband der Augenärzte Deutschlands e. V.DüsseldorfDeutschland
  2. 2.Deutsche Ophthalmologische GesellschaftMünchenDeutschland
  3. 3.Retinologische Gesellschaft e. V.FreiburgDeutschland

Personalised recommendations